Maat Pharma SA Cash Flow Conversion Efficiency

Latest as of June 2025: -1.853x

Maat Pharma SA cash flow conversion efficiency. Based on the latest financial reports, Maat Pharma SA (MAAT) has a cash flow conversion efficiency ratio of -1.853x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-15.37 Million ≈ $-17.97 Million USD) by net assets (€8.29 Million ≈ $9.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Maat Pharma SA (2017–2024)

Cash flow conversion efficiency of Maat Pharma SA from 2017 to 2024. This chart illustrates how Maat Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MAAT share price today for real-time trading data and today's change.

Maat Pharma SA Cash Flow Conversion Ratio Explained

Maat Pharma SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Maat Pharma SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Maat Pharma SA ranked by their cash flow conversion efficiency. Also see MAAT company net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
First Au Ltd AU:FAU	-0.443x
Daebo Magnetic Co.Ltd KQ:290670	-0.063x
First Graphene Ltd AU:FGR	-0.220x
Milae Bioresources Co. Ltd KQ:218150	-0.006x
MIRA Pharmaceuticals, Inc. Common Stock NASDAQ:MIRA	-0.148x
Petratherm Ltd AU:PTR	-0.044x
Jasa Kita Bhd KLSE:8648	-0.020x
Bonava AB (publ) ST:BONAV-A	-0.022x

Annual Cash Flow Conversion Efficiency for Maat Pharma SA (2017–2024)

The table below shows the annual cash flow conversion efficiency of Maat Pharma SA from 2017 to 2024. Review financial flexibility index of Maat Pharma SA to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€10.34 Million ≈ $12.08 Million	€-22.04 Million ≈ $-25.77 Million	-2.132x	-133.76%
2023-12-31	€20.47 Million ≈ $23.93 Million	€-18.67 Million ≈ $-21.83 Million	-0.912x	-94.04%
2022-12-31	€26.81 Million ≈ $31.34 Million	€-12.61 Million ≈ $-14.74 Million	-0.470x	-136.32%
2021-12-31	€39.86 Million ≈ $46.60 Million	€-7.93 Million ≈ $-9.27 Million	-0.199x	+45.47%
2020-12-31	€15.94 Million ≈ $18.63 Million	€-5.81 Million ≈ $-6.80 Million	-0.365x	-133.18%
2019-12-31	€-4.57 Million ≈ $-5.34 Million	€-5.02 Million ≈ $-5.87 Million	1.099x	+136.04%
2018-12-31	€1.27 Million ≈ $1.48 Million	€-3.87 Million ≈ $-4.53 Million	-3.050x	-315.12%
2017-12-31	€5.27 Million ≈ $6.16 Million	€-3.87 Million ≈ $-4.53 Million	-0.735x	--

About Maat Pharma SA

PA:MAAT France Biotechnology

Market Cap

$22.58 Million

€19.31 Million EUR

Market Cap Rank

#24580 Global

#393 in France

Share Price

€1.03

Change (1 day)

+1.18%

52-Week Range

€0.91 - €7.78

All Time High

€13.95